AV-TRIM: GLP-3 (LY3437943) Research Peptide

AV-TRIM is listed as a GLP-3 (LY3437943) research peptide. LY3437943 is an investigational 39-residue peptide studied for activity at three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG).

GLP-3 is an informal designation used in the research peptide marketplace, not an official scientific name. AV-TRIM is offered as 10 mg of lyophilized (freeze-dried) powder in a sealed vial for nonclinical laboratory research. The identity and composition of individual production lots require batch-specific verification.

Triple-Hormone Receptor Research

LY3437943 has been studied as a triple-receptor agonist because it demonstrates activity at three distinct receptor systems in experimental research.

These descriptions identify biological pathways studied in relation to the investigational molecule. They are not instructions for use or claims regarding the effects of AV-TRIM research material.

Discovery and Preclinical Characterization

Scientists at Eli Lilly and Company described the investigational compound LY3437943 in a 2022 publication by Coskun and colleagues in Cell Metabolism.

Their research included in vitro receptor assays and experiments in mice. In laboratory assays, the compound demonstrated relatively balanced activity at glucagon and GLP-1 receptors, with greater activity at the GIP receptor.

View Coskun et al. (2022), Cell Metabolism

Molecular Structure and Chemical Modifications

The published molecular structure of LY3437943 contains 39 amino acid residues, including modified amino acids not found among the twenty standard protein-building amino acids.

The complete systematic chemical designation of the investigational molecule is available in the FDA substance record, UNII NOP2Y096GV, and the PubChem substance database.

FDA Substance Record
|
PubChem Substance Record

Published Phase 2 Clinical Research

LY3437943 has been investigated in randomized, double-blind, placebo-controlled clinical trials conducted as part of its pharmaceutical development program.

A 2023 publication by Jastreboff and colleagues in the New England Journal of Medicine described a 48-week phase 2 study involving 338 adults.

View Jastreboff et al. (2023), NEJM

A separate phase 2 study by Rosenstock and colleagues, published in The Lancet in 2023, enrolled 281 adults across 42 United States research centers. That investigation included dulaglutide as an active comparator.

View Rosenstock et al. (2023), The Lancet

These studies examined investigational pharmaceutical material within controlled clinical research programs funded by Eli Lilly, the developer. Their findings do not establish the identity, purity, equivalence, or suitability of AV-TRIM laboratory research vials.

Investigational Development Status

LY3437943 has been studied through multiple phases of pharmaceutical research, including phase 3 clinical development. Its investigational status and ongoing studies can be reviewed through publicly accessible research registries.

ChEMBL identifies the compound under CHEMBL5095485. ClinicalTrials.gov provides information about registered clinical investigations associated with the development identifier.

View ChEMBL Compound Record
|
View ClinicalTrials.gov Studies

Frequently Asked Questions